A website to explore the TINITALY/01 DEM

In 2007, a new digital elevation model (DEM) of the whole Italian territory, named TINITALY/01, was presented by Tarquini et al. [2007]. This DEM was the final result of the DIGITALIA project supported by the Italian Ministero dell’Ambiente e della Tutela del Territorio in the framework of a general agreement involving the Istituto Nazionale di Geofisica e Vulcanologia (INGV). The whole database of this DEM, in the form of a 10 m cell size grid, is available to the INGV research community at the web portal Kharita (http://kharita.rm.ingv.it/dmap/). Tarquini et al. [2007] mentioned in short a dedicated website (http://webgis.pi.ingv.it/), where authorized users were allowed to explore full resolution nadiral or perspective shaded relief images (in stereo or conventional format) obtained from the TINITALY/01 DEM. The navigation of this website is now opened to the public. The present technical report illustrates this website, describing its content and unfolding related technological aspects

Multiview 3D reconstruction in geosciences

Multiview three-dimensional (3D) reconstruction is a technology that allows the creation of 3D models of a given scenario from a series of overlapping pictures taken using consumer-grade digital cameras. This type of 3D reconstruction is facilitated by freely available software, which does not require expert-level skills. This technology provides a 3D working environment, which integrates sample/field data visualization and measurement tools. In this study, we test the potential of this method for 3D reconstruction of decimeter-scale objects of geological interest. We generated 3D models of three different outcrops exposed in a marble quarry and two solids: a volcanic bomb and a stalagmite. Comparison of the models obtained in this study using the presented method with those obtained using a precise laser scanner shows that multiview 3D reconstruction yields models that present a root mean square error/average linear dimensions between 0.11 and 0.68%. Thus this technology turns out to be an extremely promising tool, which can be fruitfully applied in geosciences

Release of a 10-m-resolution DEM for the Italian territory: Comparison with global-coverage DEMs and anaglyph-mode exploration via the web

The 10-m-resolution TINITALY/01 DEM (Tarquini et al., 2007) is compared with the two, coarser-resolution, global-coverage, spaceborne-based SRTM and ASTER DEMs and with a high-resolution, LIDAR-derived DEM. Afterwards, we presented a webGIS which allows to explore a 10-m-resolution anaglyph layer showing the landforms of the whole Italian territory in 3D. The webGIS (http://tinitaly.pi.ingv.it/) is open to the public, and can be used to carry out a preliminary analysis of landforms. The TINITALY/01 DEM is available for scientific purposes on the basis of a research agreement (see the above website or write to [email protected])

Long-term efficacy and safety of neridronate treatment in patients with complex regional pain syndrome type 1: a pre-specified, open-label, extension study

Background: No data on the permanent and curative effect of bisphosphonate treatment in patients with complex regional pain syndrome type-1 (CRPS-1) are currently available. The aim of this pre-specified, open-label, observational study was to evaluate the long-term efficacy and safety of neridronate treatment. Design: A pre-specified, open-label, extension study. Methods: Patients treated with intramuscular (IM) placebo in the double-blind phase of the study were assigned to 100 mg intravenous (IV) neridronate treatment administered 4 times over 10 days. These patients, together with those previously treated with 400 mg IM neridronate, were followed for 1 year. Efficacy was assessed using a visual analogue scale (VAS) pain score. Changes in clinical signs and symptoms, quality of life (QoL) using the Short Form Health Survey (SF-36), and the McGill Pain Questionnaire were also assessed. Results: Benefits on pain, clinical and functional measures were maintained and further improved over 12 months in most patients treated with neridronate administered either IM or IV. In IM-treated patients, the percentage of those defined as responders (VAS score reduction ≥ 50%) progressively increased up to day 360 to 32 of 35 patients (91.4%). Among the 27 patients referred to as responders at the end of the double-blind phase, 26 reported the same result at day 360 (96.3%). In IV-treated patients, a responder rate of 88% (22 out 25) was found at day 360 (p = 0.66 between groups). Consistent improvements were also observed for all clinical signs and functional questionnaire. No drug-related adverse events were reported during the study. Conclusion: In patients with acute CRPS-1, the benefit in pain, clinical, and functional measures observed a few weeks after neridronate treatment administered either IM or IV is maintained and further improved over 12 months. Parenteral neridronate induces permanent disease remission preventing chronic pain and motor dysfunction. Trial registration: EU Clinical Trials Register (EudraCT Number): 2014-001156-2

Intramuscular neridronate for the treatment of complex regional pain syndrome type 1: a randomized, double-blind, placebo-controlled study

Background: Complex regional pain syndrome type-1 (CRPS-1) is a severely disabling painful disease challenging to treat. This multicenter, randomized, double-blind placebo-controlled trial examined the efficacy of intramuscular (i.m.) neridronate in CRPS-1 patients. Methods: A total of 78 patients diagnosed with CRPS-1 (aged 59.5 ± 10.3, 66.7% female) were randomly assigned to 25 mg (i.m.) neridronate (N = 41) given once daily for 16 consecutive days or placebo control (N = 37). Efficacy was assessed after 30 days using a visual analogue scale (VAS) pain score and the number of patients achieving ⩾50% reduction in VAS score. Change in clinical signs and symptoms, quality of life (QoL) using Short Form Health Survey (SF-36) and the McGill Pain Questionnaire were also assessed. Results: After 30 days, VAS score decreased significantly to a greater extent in neridronate-treated patients versus placebo (31.9 ± 23.3 mm versus 52.3 ± 27.8 mm, p = 0.0003). Furthermore, the proportion of patients achieving a VAS reduction of ⩾50% was greater in the neridronate group (65.9% versus 29.7%, p = 0.0017). Clinical signs and symptoms were improved significantly in the neridronate group versus placebo for edema (72.5% versus 79.9%, p = 0.03), pain during motion (70% versus 83.3%, p = 0.0009), allodynia (20% versus 63.3%, p = 0.0004), and hyperalgesia (20% versus 56.7%, p = 0.0023). Whereas no difference was observed for QoL measures using the SF-36 questionnaire, three of the four pain variables using the McGill Pain Questionnaire improved significantly in the neridronate group. No serious drug-related adverse events were reported during the study. Conclusion: In patients with acute CRPS-1, i.m. injections of 25 mg neridronate were associated with clinically relevant benefit compared with placebo controls. Trial registration: EU Clinical Trials Register: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001156-2

Early and longer term effects of gastric bypass surgery on tissue-specific insulin sensitivity and beta cell function in morbidly obese patients with and without type 2 diabetes

n/

Long-term effects of bariatric surgery on meal disposal and beta-cell function in diabetic and nondiabetic patients.

Gastric bypass surgery leads to marked improvements in glucose tolerance and insulin sensitivity in obese type 2 diabetes; the impact on glucose fluxes in response to a physiological stimulus - such as a mixed meal (MTT) - has not been determined. We administered an MTT to 12 obese type 2 diabetic patients (T2D) and 15 obese nondiabetic subjects (ND) before and one year after surgery (10 T2D and 11 ND) using the double-tracer technique and modeling of ß-cell function. In both groups postsurgery, tracer-derived appearance of oral glucose was biphasic, a rapid increase followed by a sharp drop, a pattern that was mirrored by postprandial glucose levels and insulin secretion. In diabetic patients, surgery lowered fasting and postprandial glucose levels; peripheral insulin sensitivity increased in proportion to weight loss (∼30%), ß-cell glucose sensitivity doubled but did not normalize (viz. 21 nonsurgical obese and lean controls). Endogenous glucose production, however, was less suppressed during the MMT as the combined result of a relative hyperglucagonemia and the rapid fall in plasma glucose and insulin levels.We conclude that, in type 2 diabetes bypass surgery changes the postprandial response to a dumping-like pattern, improves glucose tolerance, ß-cell function, and peripheral insulin sensitivity but worsens endogenous glucose output in response to a physiological stimulus